Uncategorized

Sanofi requests removal of Tzield from CNPV program after Høeg gets involved

Published

on

Acting Center for Drug Evaluation and Research Director Tracy Beth Høeg reportedly disagreed with staff who wanted to approve Sanofi’s type 1 diabetes drug. It’s far from the first time a political appointee has allegedly meddled in a recent FDA decision.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version